Kura Oncology (KURA) announced new preliminary data from its farnesyl transferase inhibitor, FTI, programs – darlifarnib and tipifarnib – presented at the 2025 European Society for Medical Oncology, ESMO, Congress in Berlin, Germany, from October 17 – 21, 2025. Key points: FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies; Early clinical and preclinical data support darlifarnib’s potential to enhance clinical benefit of PI3Kalpha-, KRAS- and tyrosine kinase inhibitors; 50% objective response rate and 80% disease control rate in renal cell carcinoma cohort of darlifarnib plus cabozantinib in ongoing dose-escalation clinical trial
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology management to meet with Cantor
- Kura Oncology Expands Inducement Option Plan Shares
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology, Kyowa Kirin doses first patient of KOMET-007 trial
- Kura Oncology’s Promising Developments in AML Treatment: Buy Rating Affirmed by Joseph Pantginis